In the realm of endocrine pharmacology, precise hormonal control is paramount. Cabergoline stands as a cornerstone in the management of hyperprolactinemia, distinguished by its selective action and favorable profile. GenLabs is proud to introduce its pharmaceutical-grade Cabergoline 0.50mg tablets, meticulously formulated in a convenient 30-tablet pack. This product embodies our commitment to excellence, offering researchers, clinicians, and informed users a tool of unmatched purity, consistency, and potency. Each 0.50mg tablet is the result of stringent manufacturing processes, ensuring reliable performance for studies and applications focused on prolactin suppression and dopamine receptor agonism.
This comprehensive description details the science of Cabergoline, its primary and investigational applications, the GenLabs quality advantage, and a complete usage framework to ensure informed and responsible handling.
Cabergoline is a potent, long-acting ergot derivative dopamine D2-receptor agonist. Its therapeutic and research value stems from a highly specific mechanism:
Dopamine Receptor Agonism: It directly stimulates dopamine receptors (specifically D2 subtypes) in the pituitary gland.
Prolactin Inhibition: Dopamine is the primary Prolactin-Inhibiting Factor (PIF). By mimicking dopamine, Cabergoline effectively suppresses the synthesis and secretion of prolactin from the anterior pituitary lactotroph cells.
High Selectivity & Half-Life: Unlike earlier ergot alkaloids, Cabergoline exhibits a high affinity for dopamine receptors with minimal action on serotonin or alpha-adrenergic receptors. Its elimination half-life is exceptionally long (approximately 63-69 hours), allowing for sustained prolactin suppression with less frequent dosing, leading to more stable hormonal levels and improved user adherence in clinical settings.
This targeted action makes it a premier agent for conditions and research models driven by elevated prolactin.
GenLabs Cabergoline 0.50mg serves critical roles in both established medicine and advanced research protocols.
1. Management of Hyperprolactinemia:
Hyperprolactinemia—elevated prolactin levels—can arise from pituitary prolactinomas (adenomas), idiopathic causes, or certain medications. Consequences include:
In Females: Galactorrhea (inappropriate lactation), menstrual irregularities, anovulation, and infertility.
In Males: Hypogonadism, decreased libido, erectile dysfunction, gynecomastia, and infertility.
Cabergoline is a first-line treatment, effectively normalizing prolactin levels, restoring gonadal function, and reducing tumor size in prolactin-secreting adenomas.
2. Treatment of Prolactin-Secreting Pituitary Adenomas:
For both microadenomas and macroadenomas, Cabergoline’s efficacy in shrinking tumor mass and controlling hormonal secretion is well-documented, often rendering surgery unnecessary.
3. Post-Cycle Therapy (PCT) & Hormonal Recovery in Androgen Research:
Within investigative androgen models, the use of aromatizable compounds can elevate prolactin alongside estrogen. Elevated prolactin can exacerbate side effects like gynecomastia and suppress endogenous testosterone production. Cabergoline is incorporated into some advanced PCT or on-cycle support protocols to:
Normalize prolactin levels.
Mitigate prolactin-related side effects.
Support the restoration of the hypothalamic-pituitary-gonadal (HPG) axis in conjunction with other agents like SERMs.
4. Parkinson’s Disease Research:
As a dopamine agonist, Cabergoline has been used in studies pertaining to Parkinson’s disease, often as an adjunct to levodopa, to improve motor control and reduce "off" time.
Important Disclaimer: This product is strictly for laboratory research purposes and chemical analysis. It is not intended for human consumption, nor is it a drug, food, or supplement. It is sold solely to qualified research professionals and institutions.
Why choose GenLabs Cabergoline 0.50mg? Our product is engineered to meet the exacting standards required for reproducible and reliable research.
Ultra-Pure Raw Materials: We source active pharmaceutical ingredients (API) from certified, audited suppliers, guaranteeing a base material of >99% purity.
Precision Dosing: Each tablet contains exactly 0.50mg of active Cabergoline. Our state-of-the-art blending and tableting processes ensure uniform distribution of the API throughout the entire batch, guaranteeing dose consistency from tablet to tablet and pack to pack.
Stringent Manufacturing Protocols: Produced in a GMP (Good Manufacturing Practice) compliant facility, every step—from weighing and mixing to compression, coating, and packaging—follows rigorous quality control (QC) and quality assurance (QA) protocols.
Independent Third-Party Verification: Batches are routinely analyzed by independent laboratories using High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry to confirm identity, purity, potency, and the absence of contaminants or heavy metals.
Secure & Discreet Packaging: The 30-tablet pack is sealed in a tamper-evident, light-resistant container with desiccant to ensure long-term stability and integrity. Discreet shipping protects your privacy.
Presentation: Each pack contains 30 tablets, each dosed at 0.50mg of Cabergoline.
Typical Investigational Dosing (Based on Clinical Literature):
For Hyperprolactinemia Research: Dosing often starts at 0.25mg (half a tablet) twice per week. This can be titrated upwards by 0.25mg increments every 4-8 weeks based on prolactin level assays, with a common therapeutic range of 0.5mg to 2.0mg per week, split into two or more doses.
For PCT/Endocrine Recovery Models: Protocols vary significantly but often involve lower, less frequent dosing (e.g., 0.25mg - 0.50mg twice per week) for a limited duration (4-6 weeks), always guided by hormonal assay data.
Administration: In clinical practice, it is typically administered orally with food to minimize potential gastrointestinal discomfort.
Critical Precautions & Potential Side Effects (From Clinical Data):
Dopaminergic Effects: Nausea, headache, dizziness, postural hypotension, and fatigue are common initially and often subside with continued use. Taking at bedtime can mitigate some effects.
Impulse Control Disorders: Rare but serious side effects can include pathological gambling, increased libido (hypersexuality), binge eating, and compulsive shopping. Research monitoring must account for behavioral changes.
Cardiac Valvulopathy Risk: Long-term, high-dose use of some ergot-derived dopamine agonists has been associated with an increased risk of fibrotic heart valve damage. Standard research and clinical doses for prolactin control carry a much lower risk, but regular monitoring is prudent in long-term models.
Contraindications: Not for use in models with hypersensitivity to ergot alkaloids, uncontrolled hypertension, or a history of cardiac valvular disorders.
Storage: Store in a cool, dry place at room temperature (15-25°C/59-77°F), protected from light and moisture. Keep out of reach of unauthorized personnel.
GenLabs Cabergoline 0.50mg / 30 Tablets is more than a chemical; it is a precision instrument for endocrine system research. Designed for the serious researcher who will not compromise on quality, it provides a reliable, consistent, and potent means of exploring prolactin’s role in physiology and pathology.
By choosing GenLabs, you align with a brand dedicated to scientific integrity, product transparency, and unwavering quality control. We supply the tools for discovery—you advance the science.
Order your supply of GenLabs Cabergoline 0.50mg today and experience the confidence that comes with premium research compounds.
On all orders is set at $25.00
Protected by Bitcoin
On all huge orders